Clinical Trials on Epstein Barr Virus Associated Non Hodgkin's Lymphoma

Total 4914 results

University of Miami

Terminated

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Epstein Barr Virus Associated Non Hodgkin's Lymphoma | Epstein Barr Virus Associated Hodgkin's Lymphoma | Post-Transplant Lymphoproliferative Disease

United States
Viracta Therapeutics, Inc.

Recruiting

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

EBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOS

United States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Germany, Canada, Brazil, Australia, France, Malaysia, Hong Kong, Israel
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)

Lymphoproliferative Disorders | Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | NonHodgkin Lymphoma | EBV-Related PTLD | EBV Related Lymphoma | EBV Related Hodgkin's Lymphoma

United States
University of Aarhus
Aarhus University Hospital

Completed

Early Detection of Epstein-Barr Virus Related Disease.

Epstein-Barr Virus Infections | Post-transplant Lymphoproliferative Disorder | Hemophagocytic Lymphohistiocytoses | Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | Mononucleosis | Epstein-Barr Virus Related Malignancy | Epstein-Barr Viraemia | Hemophag...

Denmark
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | EBV Positive Plasma Cell Neoplasm

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Terminated

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Burkitt Lymphoma | Non-Hodgkins Lymphoma | Atypical Burkitt Lymphoma

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Viracta Therapeutics, Inc.

Completed

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Lymphoproliferative Disorders | Epstein-Barr Virus Associated Lymphoma

United States, Brazil
Seoul National University Hospital
Gilead Sciences; Konkuk University Hospital

Unknown

To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Burkitt's

Korea, Republic of
New York Medical College
Johns Hopkins University; M.D. Anderson Cancer Center; Baylor College of Medicine and other collaborators

Terminated

Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

Hodgkins Lymphoma

United States
Samsung Medical Center

Completed

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Korea, Republic of
Eutilex

Recruiting

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

EBV Associated Extranodal NK/T-cell Lymphoma | EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma

Korea, Republic of
University of Southern California

Terminated

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Primary Effusion Lymphomas

United States
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients

Childhood Burkitt Lymphoma | Childhood Lymphoblastic Lymphoma

United States
St. Jude Children's Research Hospital

Completed

Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL

Non-Hodgkin Lymphoma | Acute Lymphoblastic Leukemia, Mature B-Cell

United States
Northern Italy Leukemia Group

Completed

Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma

Burkitt Lymphoma | B-ALL

Italy
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin Lymphoma

United States
Atara Biotherapeutics

No longer available

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Epstein-Barr Virus (EBV) Infections | EBV+ Associated Lymphoma | EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Epstein-Barr Viremia | Lymphoma, AIDS-related | Epstein-Barr Virus-associated Lymphoproliferative... and other conditions
Samsung Medical Center

Completed

Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

Korea, Republic of
Milton S. Hershey Medical Center
National Cancer Institute (NCI)

Unknown

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Lymphoma

United States
Beijing Friendship Hospital

Recruiting

Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT

Chronic Active Epstein-Barr Virus Infection | Virus-Associated Hemophagocytic Syndrome

China
Jennifer Crombie, MD
Merck Sharp & Dohme LLC

Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma Refractory | Primary Mediastinal Large B-Cell Lymphoma Recurrent | Epstein-Barr Virus Positive Diffuse Large...

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus

Healthy | Epstein Barr Virus Infection

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Burkitt Lymphoma | Diffuse Large B-cell Lymphoma | Primary CNS Lymphoma | Primary Mediastinal Lymphoma | Non-hodgkin Lymphoma,B Cell

Russian Federation
Gruppo Italiano Multiregionale per lo studio dei...
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients (CFM)

Lymphoblastic Lymphoma | Diffuse Large Cell Lymphoma | Burkitt's Lymphoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Atara Biotherapeutics
Memorial Sloan Kettering Cancer Center

Completed

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Burkitt Lymphoma | Plasmablastic Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large Cell Lymphoma | B-Cell Neoplasm

United States
ModernaTX, Inc.

Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Epstein-Barr Virus Infection

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (MABEL)

Nasopharyngeal Carcinoma | Hodgkin Disease | Non-Hodgkin Lymphoma | Severe Chronic Active Epstein Barr Virus | T/NK-lymphoproliferative Disease | Smooth Muscle Tumor

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Double Cord Versus Haploidentical (BMT CTN 1101)

Follicular Lymphoma | Hodgkin Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Burkitt's Lymphoma

United States
Medical Research Council

Completed

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Lymphoma | Leukemia

United Kingdom
PETHEMA Foundation

Completed

Rituximab Combined With Chemotherapy in Burkitt's Lymphoma

Acute Lymphoblastic Leukemia | Burkitt's Lymphoma

Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Lymphoma | Leukemia

United States
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Terminated

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Burkitt Lymphoma

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

LMBA02 Protocol for Patients With a Burkitt Lymphoma

Burkitt Lymphoma

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Lymphoma | Acute Lymphocytic Leukemia

United States
French Africa Pediatric Oncology Group

Recruiting

Recommendations for the Treatment of Children With Burkitt's Lymphoma (GFALMB2019)

Burkitt Lymphoma

Burkina Faso, Congo, The Democratic Republic of the, Côte D'Ivoire, Mali, Madagascar, Senegal
Northwestern University
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Lymphoma | Leukemia

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Burkitt's Lymphoma | Burkitt'S-like Lymphoma

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
Henogen

Completed

Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Epstein Barr Virus (EBV) Infection

Belgium
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States

Clinical Trials on Epstein Barr Virus Associated Non Hodgkin's Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations